← Back
Data updated: Mar 10, 2026
AstraZeneca
AZN OncologyRespiratoryCardiovascular
Anglo-Swedish pharma with strength in oncology, cardiovascular, and respiratory. Key drugs include Tagrisso, Farxiga, and Imfinzi. COVID-19 vaccine partner with Oxford.
$54.1B
Revenue (2024)
$220.0B
Market Cap
-
Trials
79
Approved (2yr)
Key Drugs
Recent Activity
CALQUENCE 2026-02-19
Efficacy
CALQUENCE 2026-02-19
Efficacy
FUROSEMIDE 2026-01-08
WAINUA (AUTOINJECTOR) 2025-12-17
Labeling
IMFINZI 2025-11-25
Efficacy
KOSELUGO 2025-11-19
Labeling
KOSELUGO 2025-11-19
Efficacy
TRUQAP 2025-11-14
Labeling
BEYFORTUS 2025-10-20
Efficacy
TEZSPIRE 2025-10-17
Efficacy
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 52%
7 drugs Phase 3: 124 Phase 2: 66 Phase 1: 109
Respiratory 25%
7 drugs Phase 3: 57 Phase 2: 27 Phase 1: 56
Cardiovascular 9%
5 drugs Phase 3: 15 Phase 2: 13 Phase 1: 22
Metabolic 7%
2 drugs Phase 3: 10 Phase 2: 14 Phase 1: 31
Immunology 6%
1 drugs Phase 3: 10 Phase 2: 11 Phase 1: 16
Pipeline Strength Pro
Loading...
Competitors Pro
Novartis big-pharma
Oncology, Cardiovascular, Immunology, Respiratory
Merck big-pharma
Oncology, Cardiovascular, Immunology, Metabolic
Boehringer Ingelheim big-pharma
Metabolic, Oncology, Respiratory, Immunology, Cardiovascular
Johnson & Johnson big-pharma
Oncology, Immunology, Cardiovascular, Metabolic
Sanofi big-pharma
Metabolic, Oncology, Immunology, Respiratory
Active (35)
WAINUA (AUTOINJECTOR) TRUQAP BEYFORTUS SYMBICORT AEROSPHERE AIRSUPRA IMJUDO TEZSPIRE SAPHNELO BREZTRI AEROSPHERE KOSELUGO LOKELMA FASENRA CALQUENCE IMFINZI BEVESPI AEROSPHERE TAGRISSO LYNPARZA XIGDUO XR NEXIUM 24HR FARXIGA BRILINTA DALIRESP SYMBICORT BYETTA CRESTOR PRILOSEC OTC FASLODEX NEXIUM PULMICORT RESPULES ARIMIDEX CASODEX RHINOCORT PRILOSEC NALOXONE HYDROCHLORIDE XYLOCAINE W/ EPINEPHRINE
Discontinued (38)
FUROSEMIDE BYDUREON BCISE BYDUREON PEN BYDUREON XYLOCAINE ONGLYZA KOMBIGLYZE XR TENORMIN QTERN NEXIUM IV DROPERIDOL IRESSA QTERNMET XR SYMLIN BRETYLIUM TOSYLATE ZOMIG-ZMT EMLA EPANOVA AQUASOL A PLENDIL NOLVADEX LEXXEL PULMICORT NEUTREXIN METAPROTERENOL SULFATE ELAVIL TONOCARD CITANEST PLAIN CITANEST CITANEST FORTE XYLOCAINE 5% W/ GLUCOSE 7.5% DURANEST SORBITRATE ISOETHARINE HYDROCHLORIDE FENTANYL CITRATE AND DROPERIDOL YUTOPAR DYCLONE DALGAN
Company Info
- First Approval
- 1951-05-17
- Latest
- 2026-02-19
- Applications
- 103
FDA Sponsor Names
ASTRAZENECAASTRAZENECA LPASTRAZENECA ABMEDIMMUNE ONCOLOGYASTRAZENECA PHARMS +1